 MONTREAL and CHARLOTTE, N.C., March 29, 2021 PRNewswire -- Milestone Pharmaceuticals Inc. Nasdaq: MIST, a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the first patient has been enrolled in its Phase 2 proof-of-concept study of etripamil nasal spray for the Reduction of Ventricular Rate in patients experiencing Atrial fibrillation and rapid ventricular rate AFib-RVR, or the ReVeRA study. 